Chloe Orkin
#102,336
Most Influential Person Now
British physician
Chloe Orkin's AcademicInfluence.com Rankings
Chloe Orkinphilosophy Degrees
Philosophy
#11126
World Rank
#15277
Historical Rank
Logic
#7918
World Rank
#9851
Historical Rank
Download Badge
Philosophy
Why Is Chloe Orkin Influential?
(Suggest an Edit or Addition)According to Wikipedia, Chloe Meave Orkin is a British physician and Professor of HIV/AIDS medicine at Queen Mary University of London. She works as a consultant at the Royal London Hospital, Barts Health NHS Trust. She is an internationally renowned expert in HIV therapeutics and led the first phase III clinical trial of injectable anti-retrovirals. She is immediate past Chair of the British HIV Association, where she championed the Undetectable=Untransmittable campaign within the United Kingdom. She is president elect of the Medical Women's Federation. Orkin is gay and was on the Top 100 Lesbian influencer lists in both the UK and in the US in 2020. She considers herself a medical activist and much of her work focuses on inequalities in healthcare and in Medicine.
Chloe Orkin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. (2022) (681)
- Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy (2014) (491)
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study (2013) (470)
- Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals (2010) (458)
- Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. (2010) (405)
- British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (2012) (387)
- Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study (2011) (310)
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials (2019) (309)
- Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. (2015) (288)
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. (2016) (260)
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (2019) (221)
- British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011 (2012) (206)
- British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) (2014) (195)
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial (2017) (192)
- Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study (2015) (185)
- Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease (2007) (171)
- Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial (2013) (171)
- Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study (2014) (155)
- Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. (2012) (150)
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. (2020) (145)
- Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials (2013) (142)
- British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015 (2016) (140)
- HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. (2012) (124)
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study (2018) (123)
- Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication (2008) (113)
- British HIV Association guidelines for HIV‐associated malignancies 2014 (2014) (110)
- Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count (2007) (106)
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial (2018) (102)
- HIV‐associated central nervous system diseases in the recent combination antiretroviral therapy era (2011) (98)
- Persistence of HIV-1 Transmitted Drug Resistance Mutations (2013) (98)
- Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure (2014) (98)
- Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study (2020) (89)
- Late diagnosis in the HAART era: proposed common definitions and associations with mortality (2010) (87)
- Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials (2019) (81)
- Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial (2015) (76)
- Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. (2014) (72)
- Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, (2018) (71)
- Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort (2017) (70)
- 96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study (2013) (69)
- Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study (2007) (69)
- Recent trends and patterns in HIV‐1 transmitted drug resistance in the United Kingdom (2016) (68)
- Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom (2007) (68)
- A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals (2009) (67)
- A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients (2018) (67)
- Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. (2019) (65)
- Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults (2017) (64)
- British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013 (2013) (64)
- Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy (2013) (63)
- CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK (2009) (63)
- Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. (2015) (62)
- Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma (2010) (60)
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. (2017) (59)
- Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study * (2010) (56)
- Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study (2017) (55)
- Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study (2017) (55)
- NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials (2013) (53)
- The prevalence of hepatitis C virus (HCV) infection in HIV‐positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes (2009) (52)
- HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era (2014) (52)
- Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the “Going Viral” campaign (2016) (51)
- Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? (2009) (50)
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials (2020) (49)
- Antiretroviral therapy CNS penetration and HIV-1–associated CNS disease (2011) (48)
- Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. (2021) (44)
- Potential health risks of complementary alternative medicines in HIV patients (2008) (44)
- Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations * (2010) (42)
- Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)‐B*5701 in HIV‐1‐infected UK subjects (2010) (41)
- Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. (2009) (40)
- Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials† (2018) (39)
- Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. (2013) (39)
- Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures (2007) (38)
- Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. (2010) (37)
- Long‐term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study (2011) (37)
- Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study (2011) (37)
- Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. (2007) (36)
- An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe (2010) (36)
- Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo) (2014) (35)
- Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK (2008) (33)
- Disease Progression in HIV-1–Infected Viremic Controllers (2012) (32)
- Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom? (2020) (31)
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. (2020) (31)
- The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy (2009) (31)
- Nucleoside reverse transcriptase inhibitor‐reducing strategies in HIV treatment: assessing the evidence (2018) (31)
- Data linkage reduces loss to follow-up in an observational HIV cohort study. (2010) (30)
- Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. (2003) (30)
- Week 96 analysis of rilpivirine or efavirenz in HIV‐1‐infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials (2014) (30)
- A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals (2015) (29)
- Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials. (2021) (29)
- Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. (2014) (28)
- A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). (2005) (28)
- N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients (2011) (28)
- A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study (2018) (28)
- Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters (2011) (27)
- Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TA (2019) (26)
- Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. (2019) (26)
- Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control (2018) (26)
- High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? (2015) (23)
- Factors influencing lopinavir and atazanavir plasma concentration. (2010) (23)
- Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection (2018) (23)
- A highly virulent variant of HIV-1 circulating in the Netherlands (2022) (23)
- Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. (2010) (23)
- A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). (2004) (22)
- Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. (2021) (22)
- Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? (2008) (22)
- Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study (2018) (21)
- Vitamin D deficiency in HIV: a shadow on long-term management? (2014) (21)
- Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study (2020) (20)
- Twenty‐four‐week efficacy and safety of switching virologically suppressed HIV‐1‐infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION) (2012) (20)
- Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study (2008) (20)
- Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. (2011) (20)
- Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy (2016) (20)
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial (2020) (19)
- Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases (2020) (19)
- Gender disparities in coronavirus disease 2019 clinical trial leadership (2021) (18)
- Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials (2020) (18)
- Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm3 (2008) (17)
- Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial. (2013) (17)
- Second-Line Protease Inhibitor-Based Antiretroviral Therapy after Non-Nucleoside Reverse Transcriptase Inhibitor Failure: The Effect of a Nucleoside Backbone (2013) (17)
- Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series (2022) (15)
- Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women? (2016) (15)
- A systematic review of risk of HIV transmission through biting or spitting: implications for policy (2018) (15)
- Routine HIV testing within the emergency department of a major trauma centre: a pilot study (2015) (15)
- Chronic Kidney Disease Risk in African and Caribbean Populations With HIV (2018) (15)
- Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study (2013) (15)
- Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study (2013) (15)
- Acute kidney injury in COVID-19: multicentre prospective analysis of registry data (2021) (14)
- Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2 (2017) (14)
- Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection (2020) (14)
- TestMeEast: a campaign to increase HIV testing in hospitals and to reduce late diagnosis (2016) (14)
- ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults (2010) (14)
- Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department – uncovering the iceberg? (2018) (14)
- Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression (2014) (14)
- Development and application of a new measure of engagement in out‐patient HIV care (2016) (13)
- A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England (2017) (13)
- LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial (2018) (12)
- Pneumococcal vaccination in people living with HIV. (2015) (11)
- HIV Diagnosis at CD4 Count Above 500 Cells/mm3 and Progression to Below 350 Cells/mm3 Without Antiretroviral Therapy (2007) (11)
- Monkeypox (2022) (11)
- Changes in weight and BMI with first-line doravirine-based therapy (2020) (10)
- Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016 (2019) (10)
- Opt-out HIV testing in adult critical care units (2014) (10)
- Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection (2014) (10)
- Clinical outcomes of patients with and without HIV hospitalized with COVID‐19 in England during the early stages of the pandemic: a matched retrospective multi‐centre analysis (RECEDE‐C19 study) (2021) (9)
- Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update) (2014) (9)
- P0887 : C-edge co-infected: phase 3 study of grazoprevir/elbasvir in patients with HCV/HIV (2015) (9)
- Simeprevir ( TMC 435 ) With Pegylated Interferon / Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1 : A Phase 3 Study (2014) (9)
- Estimated glomerular filtration rate slopes on tenofovir alafenamide (2020) (8)
- Non‐uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK (2012) (8)
- Implementing U=U in clinical practice: results of a British HIV association members survey (2020) (8)
- Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation (2015) (8)
- O322: Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV co-infected patients with HCV GT1-4 infection: the PHOTON-1 and -2 Trials (2015) (8)
- ‘Just another vial…’: a qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK (2019) (8)
- Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis. (2020) (7)
- Effi cacy and safety of grazoprevir ( MK-5172 ) and elbasvir ( MK-8742 ) in patients with hepatitis C virus and HIV co-infection ( C-EDGE CO-INFECTION ) : a non-randomised , open-label trial (2015) (7)
- Virological response to initial antiretroviral regimens containing abacavir or tenofovir. (2009) (7)
- Uptake and Outcome of Combination Antiretroviral Therapy in Men Who Have Sex with Men According to Ethnic Group: The UK CHIC Study (2011) (7)
- Ethnicity and acute hospital admissions: Multi-center analysis of routine hospital data (2021) (7)
- Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction (2018) (7)
- Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens (2017) (7)
- Long-acting injectable HIV therapies: the next frontier (2020) (7)
- Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy? (2012) (7)
- Speaker Abstracts (2012) (6)
- Introducing opt-out HIV testing in an acute medical admissions unit: does it improve testing uptake in those with lobar pneumonia? (2014) (6)
- Uptake of Tenofovir-Based Antiretroviral Therapy among HIV–HBV-Coinfected Patients in the EuroSIDA Study (2018) (6)
- Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study (2009) (6)
- Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice (2007) (6)
- Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV (2019) (6)
- Mpox in people with advanced HIV infection: a global case series (2023) (6)
- Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance (2018) (6)
- Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance (2018) (6)
- Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe (2018) (5)
- Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate (2018) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study (2019) (5)
- THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection (2019) (5)
- A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK (2020) (5)
- Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
- week 96 efficacy and safety data: Elvitegravir/cobicistat/ emtricitabine/tenofovir Df (quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir Df in treatment-naïve Hiv-1-infected patients : P139 (2013) (4)
- Monkeypox vaccination—an opportunity for HIV prevention (2022) (4)
- Predicting virological decay in patients starting combination antiretroviral therapy (2016) (4)
- Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis. (2019) (3)
- Two-drug regimens for HIV treatment. (2022) (3)
- HIV research trials versus standard clinics for antiretroviral-naïve patients: the outcomes differ but do the patients? (2016) (3)
- An innovative joint approach to HIV and lymphoma care (2011) (3)
- BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022 (2022) (3)
- A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada (2017) (3)
- Public understanding and awareness of and response to monkeypox virus outbreak: A cross-sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency. (2022) (3)
- Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents (2019) (2)
- Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV (2022) (2)
- Impact of early antiretroviral treatment on sexual behaviour in the INSIGHT Strategic Timing of Anti-Retroviral Treatment (START) Trial. (2019) (2)
- Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies (2019) (2)
- Bone mineral density, kidney function and participant‐reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir (2021) (2)
- Enrolling pregnant women with HIV into clinical trials. (2020) (2)
- Linkage to care after routine HIV, hepatitis B & C testing in the emergency department: the ‘Going Viral’ campaign (2016) (2)
- Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16–18 May 2018, Marseille, France: from HIV and comorbidities to global health (2018) (2)
- International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
- Long-acting injectable HIV therapies: the next frontier: Republication (2021) (2)
- Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. (2020) (2)
- The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences (2021) (2)
- HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era (2011) (2)
- Public understanding, awareness, and response to the monkeypox virus outbreak: A cross-sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency (2022) (2)
- Changes in Patient-reported Neuropsychiatric Outcomes during the SENSE Trial: First-line Treatment with Two Nucleoside Analogues plus Etravirine or Efavirenz (2012) (2)
- Human Monkeypox Virus Infection in Women During the 2022 Outbreaks – a Global Case Series (2022) (2)
- HIV Care and Service Development O 1 Non-AIDS mortality among people diagnosed with HIV in the era of highly-active antiretroviral therapy compared to the general population : England and Wales , 1997 – 2012 (2016) (1)
- Observational cohort study of rilpivirine (RPV) utilization in Europe (2022) (1)
- Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials (2021) (1)
- BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV 2013 Update September 2014: Consensus statement on the guidelines for treating hepatitis C in patients with HIV (2015) (1)
- Efficacy, safety and CNS effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine in a randomized controlled trial. (2021) (1)
- International Women's Day-how can I help? (2022) (1)
- The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London. (2021) (1)
- TRANxITION 144‐week results: switching virologically stable HIV patients from immediate‐release nevirapine (NVP IR) to extended‐release NVP (XR) (2012) (1)
- Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data (2018) (1)
- 543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults (2018) (1)
- P1247 : Unexpected high prevalence of HCV-viraemia (HCVRNA+) in the emergency department (ED) of a London hospital - should we be screening for HCV in ED attendees? (2015) (1)
- Hostile health-care environment could increase migrants' risk of HIV and prevent access to vital services. (2019) (1)
- Rilpivirine efficacy, virology and safety in ARV treatment‐naïve patients with viral load≤100,000 HIV‐1 RNA c/mL: ECHO and THRIVE 96‐week results (2012) (1)
- Blinded by love: Ocular syphilis as the initial manifestation of HIV: Category: Clinical lesson (2011) (1)
- Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT) (2016) (1)
- HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
- Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine (2020) (1)
- Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study (2010) (1)
- Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison (2019) (1)
- First contact: exploring relationships between HIV clinics, primary care, geography and HIV diagnoses in North East London (2011) (0)
- Sustained virological response after only 5 weeks treatment with daclatasvir/pegylated interferon and ribavirin as part of a clinical trial in a cirrhotic human immunodeficiency virus (HIV) - hepatitis C virus (HCV) co-infected patient with liver decompensation during treatment (2015) (0)
- Few men who have sex with men (MSM) attending two inner-city clinics were tested for hepatitis C virus (HCV) despite high risk: a retrospective analysis of sexual health screening in East London (2017) (0)
- Sick call in pediatric residency programs: the chief resident perspective. (1998) (0)
- multicentric Castleman disease Rituximab as retreatment for rituximab pretreated HIV-associated (2012) (0)
- 69. Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks (2021) (0)
- HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico (2015) (0)
- Gender disparities in international COVID-19 clinical trial leadership (2020) (0)
- Safety and efficacy of rilpivirine-tenofovir-emtricitabine (Eviplera (R)) in hepatitis C-HIV coinfection (2013) (0)
- 1251. 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials (2022) (0)
- Estimating the global impact of coronavirus disease 2019 on people living with HIV (2022) (0)
- Traitement VIH : Une étude internationale dans le prestigieux New England Journal of Medicine (2020) (0)
- 1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials (2018) (0)
- First study of monkeypox infection in women provides new insights to inform public health response to ongoing outbreak (2022) (0)
- Reflections and intersections: disability, ‘ableism’ and metamodern leadership (2022) (0)
- Abstracts of the 22nd Annual Conference of the British HIV Association (BHIVA), Manchester, UK, 19-22 April 2016. (2016) (0)
- Evaluation of Roche Cobas Taqman Quantitative HIV-1 RNA PCR against other HIV-1 commercial viral load tests to examine potential under-quantification (2008) (0)
- REPLY TO Lanzafame, Lattuada and Vento. (2019) (0)
- Experiences of initiating rapid antiretroviral therapy among people newly diagnosed with HIV in East London: a qualitative study (2023) (0)
- Authors' response to Drs Scourfield, Jackson and Nelson (2011) (0)
- Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Associated Burkitt’s Lymphoma (BL) (2008) (0)
- Lenacapavir in first-line therapy. (2023) (0)
- Monkeypox Virus Infection across 16 Countries - April-June 2022. Reply. (2022) (0)
- P04-35. Neutralisation activity in a geographically diverse East London cohort of HIV-1 infected patients (2009) (0)
- Does less equal more yet? (2019) (0)
- Editorial: Is it time to implement injectable antiretroviral treatments globally? (2022) (0)
- ORAL ABSTRACTS (2017) (0)
- NtRTI sparing in patients at risk of bone disease. (2015) (0)
- Outcomes of second-line ritonavir-boosted protease inhibitor (PI/r)-based ART after failure of a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART (2010) (0)
- Should HIV testing week be blood-borne-virus testing week? (2015) (0)
- Reply to Lanzafame et al (2019) (0)
- O028 Low proportion of men who have sex with men (MSM) tested for hepatitis C despite high prevalence in 2 genito-urinary medicine (GUM) clinics (2016) (0)
- HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico (2016) (0)
- TRANxITION 144 Week Results: Switching Virologically Stable HIV Patients from Immediate-release Nevirapine (NVP IR) to Extended-Release NVP (XR) (2014) (0)
- Insights into HIV-1 Capsid Inhibitors in early clinical development as antiretroviral agents (2019) (0)
- P045 Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults (2016) (0)
- Redressing Gender Imbalance in Leadership in Academic Medicine. (2021) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- Track B Clinical Science (2012) (0)
- Will earlier diagnosis of HIV infection in late presenters reduce the frequency of serious opportunistic infections? Response (2011) (0)
- P16-21. Altered T cell homeostasis and activation in HIV-1 elite suppressors with low CD4+ T-cell counts (2009) (0)
- British Society for Skin Care in Immunocompromised Individuals (2014) (0)
- IN THE HIGH COURT OF JUSTICE (2019) (0)
- Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial (2016) (0)
- The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe (2022) (0)
This paper list is powered by the following services:
Other Resources About Chloe Orkin
What Schools Are Affiliated With Chloe Orkin?
Chloe Orkin is affiliated with the following schools:
